SIGNIFICANCE OF C-MET AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER

被引：0
|
作者：
Kashiwagi, S. [1 ]
Yashiro, M. [1 ]
Aomatsu, N. [1 ]
Kawajiri, H. [1 ]
Takashima, T. [1 ]
Onoda, N. [1 ]
Ishikawa, T. [1 ]
Hirakawa, K. [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Osaka 558, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Potential therapeutic target for triple-negative breast cancer
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2012, 13 (08): : E330 - E330
  • [2] Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
    Gaule, Patricia
    Mukherjee, Nupur
    Corkery, Brendan
    Eustace, Alex J.
    Gately, Kathy
    Roche, Sandra
    O'Connor, Robert
    O'Byrne, Kenneth J.
    Walsh, Naomi
    Duffy, Michael J.
    Crown, John
    O'Donovan, Norma
    CANCERS, 2019, 11 (04):
  • [3] Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer
    Chu, Yu-Yi
    Yam, Clinton
    Chen, Mei-Kuang
    Chan, Li-Chuan
    Xiao, Min
    Wei, Yong-Kun
    Yamaguchi, Hirohito
    Lee, Pei-Chih
    Han, Ye
    Nie, Lei
    Sun, Xian
    Moulder, Stacy L.
    Hess, Kenneth R.
    Wang, Bin
    Hsu, Jennifer L.
    Hortobagyi, Gabriel N.
    Litton, Jennifer
    Chang, Jeffrey T.
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (02): : 648 - 661
  • [4] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Breen, Laura
    Gaule, Patricia B.
    Canonici, Alexandra
    Walsh, Naomi
    Collins, Denis M.
    Cremona, Mattia
    Hennessy, Bryan T.
    Duffy, Michael J.
    Crown, John
    O' Donovan, Norma
    Eustace, Alex J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1365 - 1372
  • [5] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Laura Breen
    Patricia B. Gaule
    Alexandra Canonici
    Naomi Walsh
    Denis M. Collins
    Mattia Cremona
    Bryan T. Hennessy
    Michael J. Duffy
    John Crown
    Norma O’ Donovan
    Alex J. Eustace
    Investigational New Drugs, 2020, 38 : 1365 - 1372
  • [6] c-MET aberration in triple negative breast cancers
    Zhang, H.
    BREAST, 2015, 24 : S28 - S28
  • [7] cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule, Patricia B.
    Crown, John
    O'Donovan, Norma
    Duffy, Michael J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) : 999 - 1009
  • [8] Triple-negative breast cancer: investigating potential molecular therapeutic target
    Papa, Anselmo
    Caruso, Davide
    Tomao, Silverio
    Rossi, Luigi
    Zaccarelli, Eleonora
    Tomao, Federica
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (01) : 55 - 75
  • [9] Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer
    Inanc, Mevlude
    Ozkan, Metin
    Karaca, Halit
    Berk, Veli
    Bozkurt, Oktay
    Duran, Ayse Ocak
    Ozaslan, Ersin
    Akgun, Hulya
    Tekelioglu, Fatos
    Elmali, Ferhan
    MEDICAL ONCOLOGY, 2014, 31 (01)
  • [10] CHK1 AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
    Quidville, V.
    Albiges-Sauvin, L.
    Goubar, A.
    Scott, V.
    Andre, F.
    ANNALS OF ONCOLOGY, 2011, 22 : 51 - 52
12345